B. Van Baelen

1.3k total citations
31 papers, 1.0k citations indexed

About

B. Van Baelen is a scholar working on Psychiatry and Mental health, Pharmacology and Organic Chemistry. According to data from OpenAlex, B. Van Baelen has authored 31 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Psychiatry and Mental health, 9 papers in Pharmacology and 6 papers in Organic Chemistry. Recurrent topics in B. Van Baelen's work include Dementia and Cognitive Impairment Research (12 papers), Cholinesterase and Neurodegenerative Diseases (8 papers) and Chemical synthesis and alkaloids (6 papers). B. Van Baelen is often cited by papers focused on Dementia and Cognitive Impairment Research (12 papers), Cholinesterase and Neurodegenerative Diseases (8 papers) and Chemical synthesis and alkaloids (6 papers). B. Van Baelen collaborates with scholars based in Germany, Belgium and United States. B. Van Baelen's co-authors include Martin Brecher, R. De Coster, David L. Kleinberg, S. Schwalen, John M. Davis, Shane Kavanagh, Howard Feldman, Alexander Kurz, Koen Torfs and J. Peuskens and has published in prestigious journals such as Biological Psychiatry, The Lancet Neurology and Journal of Hepatology.

In The Last Decade

B. Van Baelen

31 papers receiving 972 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B. Van Baelen Germany 18 565 301 150 84 83 31 1.0k
R. Grohmann Germany 26 1.3k 2.3× 436 1.4× 75 0.5× 51 0.6× 19 0.2× 130 2.0k
Eric Wooltorton Canada 16 332 0.6× 131 0.4× 105 0.7× 88 1.0× 21 0.3× 66 1.0k
Ruth Brauer United Kingdom 20 182 0.3× 87 0.3× 128 0.9× 140 1.7× 52 0.6× 47 1.1k
Dawn Farrell Ireland 10 326 0.6× 241 0.8× 158 1.1× 34 0.4× 68 0.8× 17 926
Thomas Shiovitz United States 16 554 1.0× 303 1.0× 146 1.0× 23 0.3× 23 0.3× 28 1.2k
J. Michael Ryan United States 21 971 1.7× 350 1.2× 737 4.9× 26 0.3× 224 2.7× 30 2.1k
M. Saleem Ismail United States 7 711 1.3× 176 0.6× 310 2.1× 17 0.2× 178 2.1× 11 1.2k
Hao Niu Spain 14 212 0.4× 68 0.2× 215 1.4× 23 0.3× 80 1.0× 28 877
R. Oakes United States 9 362 0.6× 249 0.8× 68 0.5× 304 3.6× 8 0.1× 16 1.1k
Dolors Capellà Spain 22 480 0.8× 438 1.5× 121 0.8× 41 0.5× 46 0.6× 51 1.6k

Countries citing papers authored by B. Van Baelen

Since Specialization
Citations

This map shows the geographic impact of B. Van Baelen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Van Baelen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Van Baelen more than expected).

Fields of papers citing papers by B. Van Baelen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Van Baelen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Van Baelen. The network helps show where B. Van Baelen may publish in the future.

Co-authorship network of co-authors of B. Van Baelen

This figure shows the co-authorship network connecting the top 25 collaborators of B. Van Baelen. A scholar is included among the top collaborators of B. Van Baelen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Van Baelen. B. Van Baelen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Baelen, B. Van, et al.. (2011). Galantamine and behavior in Alzheimer disease: analysis of four trials. Acta Neurologica Scandinavica. 124(5). 302–308. 38 indexed citations
2.
Richarz, Ute, et al.. (2011). Effects of Galantamine in Alzheimers Disease: Double-blind Withdrawal Studies Evaluating Sustained Versus Interrupted Treatment. Current Alzheimer Research. 8(7). 771–780. 17 indexed citations
3.
Richarz, Ute, et al.. (2011). P3‐465: Predictors to long‐term treatment response to galantamine. Alzheimer s & Dementia. 7(4S_Part_19). 1 indexed citations
4.
Kavanagh, Shane, B. Van Baelen, & Barbara Schäuble. (2011). Long-term Effects of Galantamine on Cognitive Function in Alzheimer's Disease: A Large-Scale International Retrospective Study. Journal of Alzheimer s Disease. 27(3). 521–530. 17 indexed citations
5.
6.
Maes, Frédéric, et al.. (2010). CFD models for wallshear stress estimation; a comparitive study of two complete scaffold geometries. Ghent University Academic Bibliography (Ghent University). 228–233. 1 indexed citations
7.
Maes, Frederik, et al.. (2010). CFD Models for Wall Shear Stress Estimation; a Comparative study of two Complete Scaffold geometries. 228–233. 1 indexed citations
8.
Baelen, B. Van, et al.. (2009). Optimal Dosing of Galantamine in Patients with Mild or Moderate Alzheimerʼs Disease. Drugs & Aging. 26(3). 231–239. 26 indexed citations
9.
10.
Feldman, Howard, Tuula Pirttilä, Jean‐François Dartigues, et al.. (2008). Analyses of mortality risk in patients with dementia treated with galantamine. Acta Neurologica Scandinavica. 119(1). 22–31. 16 indexed citations
11.
Feldman, Howard, Tuula Pirttilä, Jean François Dartigues, et al.. (2008). Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. International Journal of Geriatric Psychiatry. 24(5). 479–488. 46 indexed citations
12.
Burns, Alistair, Roberto Bernabei, Roger Bullock, et al.. (2008). Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. The Lancet Neurology. 8(1). 39–47. 107 indexed citations
13.
Feldman, Howard, et al.. (2005). Cognition, Function, and Caregiving Time Patterns in Patients With Mild-to-Moderate Alzheimer Disease. Alzheimer Disease & Associated Disorders. 19(1). 29–36. 88 indexed citations
14.
Baelen, B. Van, et al.. (2004). Effects of galantamine in patients with mild Alzheimer's disease. Current Medical Research and Opinion. 20(11). 1815–1820. 14 indexed citations
15.
Kurz, Alexander & B. Van Baelen. (2004). <i>Ginkgo biloba </i>Compared with Cholinesterase Inhibitors in the Treatment of Dementia: A Review Based on Meta-Analyses by the Cochrane Collaboration. Dementia and Geriatric Cognitive Disorders. 18(2). 217–226. 32 indexed citations
16.
Blesa, Rafael, Michael Davidson, Alexander Kurz, et al.. (2003). Galantamine Provides Sustained Benefits in Patients with ‘Advanced Moderate’ Alzheimer’s Disease for at Least 12 Months. Dementia and Geriatric Cognitive Disorders. 15(2). 79–87. 50 indexed citations
17.
Sano, Mary, Gordon Wilcock, B. Van Baelen, & Shane Kavanagh. (2003). The effects of galantamine treatment on caregiver time in Alzheimer's disease. International Journal of Geriatric Psychiatry. 18(10). 942–950. 46 indexed citations
18.
Fleischhacker, W. W., Paul Lemmens, & B. Van Baelen. (2001). A Qualitative Assessment of the Neurological Safety of Antipsychotic Drugs; an Analysis of a Risperidone Database. Pharmacopsychiatry. 34(3). 104–110. 12 indexed citations
19.
Peuskens, J., et al.. (2000). Effects of risperidone on affective symptoms in patients with schizophrenia. International Clinical Psychopharmacology. 15(6). 343–349. 59 indexed citations
20.
Kleinberg, David L., John M. Davis, R. De Coster, B. Van Baelen, & Martin Brecher. (1999). Prolactin Levels and Adverse Events in Patients Treated with Risperidone. Journal of Clinical Psychopharmacology. 19(1). 57–61. 242 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. Grohmann Breakdown of academic impact, for papers by Eric Wooltorton Breakdown of academic impact, for papers by Ruth Brauer Breakdown of academic impact, for papers by Dawn Farrell Breakdown of academic impact, for papers by Thomas Shiovitz Breakdown of academic impact, for papers by J. Michael Ryan Breakdown of academic impact, for papers by M. Saleem Ismail Breakdown of academic impact, for papers by Hao Niu Breakdown of academic impact, for papers by R. Oakes Breakdown of academic impact, for papers by Dolors Capellà
Rankless by CCL
2026